Superovulation strategies for assisted reproductive technologies

Seminars in Reproductive Medicine

Volumn 19, Issue 3, 2001, Pages 207-212

  Davis, O K ^a   Rosenwaks, Z ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Assisted reproductive technologies; In vitro fertilization; Ovarian stimulation; Superovulation

Indexed keywords

CLOMIFENE CITRATE; ESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; FOLLITROPIN; GONADORELIN; GONADORELIN AGONIST; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT;

ADULT; AGE; ANAMNESIS; DRUG CHOICE; DRUG EFFECT; DRUG RESPONSE; EMBRYO; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HUMAN; INDIVIDUALITY; INFERTILITY THERAPY; OOCYTE; OVULATION INDUCTION; PREGNANCY RATE; QUALITY CONTROL; REVIEW; SUPEROVULATION;

AGE FACTORS; CLOMIPHENE; EMBRYO TRANSFER; FEMALE; FERTILITY AGENTS, FEMALE; GONADOTROPINS; HUMANS; MALE; PREGNANCY; REPRODUCTIVE TECHNIQUES, ASSISTED; SUPEROVULATION;

EID: 0034756850     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18039     Document Type: Review

References (22)

1. Birth after reimplantation of a human embryo
2. Update on in vitro fertilization
3. Cumulative ovulation rate in human menopausal/human chorionic gonadotropin-treated monkeys: "Step-up" versus "step-down" dose regimens
4. Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval
5. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: A meta-analysis of randomized controlled trials
6. Improved pregnancy outcome with gonadotropin-releasing hormone agonist (GnRHa) stimulation is due to the improvement in oocyte quantity rather than quality
7. Assisted reproductive technology in the United States: 1997 Results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry
8. The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome
9. Intercycle variability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization and embryo transfer
10. Day 3 estradiol serum concentrations as prognosticators of stimulation response and pregnancy outcome in patients undergoing in vitro fertilization
11. Prognostic assessment of female fecundity
12. Highdose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome
13. Minidose gonadotropin releasing hormone agonist is the treatment of choice in poor responders with high folliclestimulating hormone levels
14. Ovarian estradiol production in vivo: Inhibitory effect of leuprolide acetate
15. Suppression and flare regimens of gonadotropin-releasing hormone agonist: Use in women with different basal gonadotropin values in an in vitro fertilization program
16. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol
17. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization
18. Incidence of severe ovarian hyperstimulation syndrome after gonadotropin releasing hormone agonist/hMG superovulation for in vitro fertilization
19. Stimulation with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression in polycystic ovarian syndrome
20. Ovulation induction for assisted reproduction
21. Dual suppression with oral contraceptives and gonadotropin releasing hormone agonists improves in vitro fertilization outcome in high responder patients
22. Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome